New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - tacrolimus 5mg - modified release capsule - 5 mg - active: tacrolimus 5mg excipient: ethanol ethylcellulose gelatin hypromellose opacode s-1-15083 red (trace, see tt70-) iron oxide red iron oxide yellow lactose monohydrate magnesium stearate sodium laurilsulfate titanium dioxide - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidney-pancreas) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

Ireland - English - HPRA (Health Products Regulatory Authority)

astellas pharma co. ltd - leuprorelin acetate - powder and solvent for solution for injection - 45 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin

Ireland - English - HPRA (Health Products Regulatory Authority)

astellas pharma co. ltd - leuprorelin acetate - powder and solvent for solution for injection - 22.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin

Ireland - English - HPRA (Health Products Regulatory Authority)

astellas pharma co. ltd - leuprorelin acetate - powder and solvent for solution for injection - 7.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - mirabegron, quantity: 50 mg - tablet, modified release - excipient ingredients: macrogol 2000000; macrogol 8000; purified water; butylated hydroxytoluene; hyprolose; magnesium stearate; hypromellose; iron oxide yellow - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence in patients with overactive bladder (oab) syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - mirabegron, quantity: 25 mg - tablet, modified release - excipient ingredients: butylated hydroxytoluene; magnesium stearate; hyprolose; purified water; macrogol 2000000; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence in patients with overactive bladder (oab) syndrome.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - chlorquinaldol; hydrocortisone butyrate - cutaneous cream - 30mg/1gram ; 1mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - chlorquinaldol; hydrocortisone butyrate - cutaneous ointment - 30mg/1gram ; 1mg/1gram

New Zealand - English - Medsafe (Medicines Safety Authority)

research associates ltd - tacrolimus 0.5mg - capsule - 0.5 mg - active: tacrolimus 0.5mg excipient: croscarmellose sodium gelatin hypromellose iron oxide yellow lactose monohydrate magnesium stearate purified water titanium dioxide - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidney-pancreas) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

New Zealand - English - Medsafe (Medicines Safety Authority)

research associates ltd - tacrolimus 1mg - capsule - 1 mg - active: tacrolimus 1mg excipient: croscarmellose sodium hypromellose lactose monohydrate magnesium stearate - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidney-pancreas) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.